# ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS

> **NCT01423175** · PHASE2 · UNKNOWN · sponsor: **Hannover Medical School** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- MDS

## Interventions

- **DRUG:** Clofarabine, ara-C
- **DRUG:** FLAMSA

## Key facts

- **NCT ID:** NCT01423175
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2015-01
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423175, "ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01423175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*